CTLT - Catalent, Inc.

NYSE - NYSE Delayed price. Currency in USD
37.80
+0.08 (+0.21%)
At close: 04:03PM EDT
36.75 -1.05 (-2.78%)
After hours: 06:35PM EDT
Stock chart is not supported by your current browser
Previous close37.72
Open37.72
Bid0.00 x 900
Ask0.00 x 800
Day's range36.93 - 37.85
52-week range31.45 - 115.33
Volume2,585,101
Avg. volume4,360,890
Market cap6.807B
Beta (5Y monthly)1.17
PE ratio (TTM)16.29
EPS (TTM)2.32
Earnings date28 Aug 2023 - 01 Sept 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est47.25
  • Zacks

    Catalent (CTLT) Expands Its Facility Capabilities in Shiga

    Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.

  • Motley Fool

    Why Catalent Stock Could Only Inch Higher Today

    Catalent (NYSE: CTLT) investors are clearly an optimistic bunch, as lately they've been taking not-so-bad-news very positively and trading up the stock. JPMorgan Chase's (NYSE: JPM) Julia Qin was the person behind the downgrade. Catalent has been a troubled company of late, and caution is clearly warranted.

  • Motley Fool

    Why Shares of Catalent Were Up Friday

    Shares of contract drug manufacturer Catalent (NYSE: CTLT) were up more than 14% Friday afternoon after the healthcare company announced updated guidance and said it was delaying its third-quarter report for a second time. It seems counterintuitive that Catalent, after downgrading guidance and saying it was not able to prepare third-quarter earnings on time, would go up in price. The company's shares had already fallen when it announced on May 8 that its earnings report and guidance would not be on May 9, as originally scheduled.

  • Yahoo Finance Video

    Stocks mixed, Foot Locker plunges, Catalent surges in morning session

    Yahoo Finance markets contributor Remy Blaire breaks down the morning market action while also taking a look at shares of Foot Locker and Catalent.

  • Business Wire

    Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

    SOMERSET, N.J., May 19, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company’s Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the "Form 12b-25") with the Securities and Exchange Commission (the "SEC"); the Company’s ongoing focus on finalizing its financial statements and other disclosures in its

  • Business Wire

    Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call

    SOMERSET, N.J., May 13, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company’s Form 12b-25 filed on May 11, 2023, with the Securities and Exchange Commission, and the Company’s ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended

  • Motley Fool

    Why Catalent Stock Was in the Red Again Today

    The out-of-favor contract drug manufacturer saw two analysts get notably less bullish on its future.

  • Zacks

    Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)

    Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

  • Motley Fool

    Why Catalent Stock Was a Disaster Today

    The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update, and in response traded the shares down by almost 26% on the day. In its press release on the matter, Catalent said that the delay stems from its discovery of certain noncash adjustments connected with its operations in Bloomington, Indiana.

  • Bloomberg

    Drug Contractor Catalent Plunges After Annual Guidance Cut, Results Delayed

    (Bloomberg) -- Catalent Inc. shares traded at their lowest in three years following cuts to its annual financial outlook that hurt investor confidence in the contract drug manufacturer.Most Read from BloombergPowell’s Bet Against Recession Looks Good — Minus the Credit Crunch and a DC StandoffTexas Mass Shooting’s Bloody Images Add to Fervor in Gun DebateWhy Airfares, Hotels and Cars Are Getting So Expensive for AmericansGoldman Shells Out $215 Million to End Case on Underpaying WomenMitch McCon

  • Motley Fool

    Why Wall Street Took a Hit From These 2 NYSE Stocks

    Monday was a relatively quiet day on Wall Street, with most major benchmarks seeing modest losses at midday. With key inflation and other economic data coming in the near future, investors are watching closely for signs of what the Federal Reserve might do on the interest rate and monetary policy front in the months to come. Both Catalent (NYSE: CTLT) and Tyson Foods (NYSE: TSN) were down by double-digit percentages as of midday, and both businesses face some challenges that shareholders aren't quite sure how they will solve.

  • Zacks

    Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

    Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

  • Business Wire

    Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance

    SOMERSET, N.J., May 08, 2023--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will be delaying the release of its third fiscal quarter results and investor conference call, previously scheduled for Tuesday, May 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than May 11, 2023. The Company now expects

  • Business Wire

    Catalent Recommends Stockholders Reject Mini-Tender Offer From TRC Capital Investment Corporation

    SOMERSET, N.J., May 05, 2023--Catalent, Inc. ("Catalent") (NYSE: CTLT) has been notified of an unsolicited "mini-tender offer" by TRC Capital Investment Corporation ("TRC") to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash. TRC’s offer price is approximately 4.43% lower than the $44.94 closing price of Catalent’s common stock on April 24, 2023, the last trading day prior to the date of the mini-tender offer (April 25, 2023).

  • Zacks

    Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates

    Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Motley Fool

    Is It Time to Buy the S&P 500's 3 Worst-Performing April Stocks?

    Although the S&P 500 mustered a 1.5% gain last month, a bunch of tickers went south ... way south. Technically speaking, failed bank First Republic is the S&P 500's biggest loser from last month. Because JPMorgan Chase will soon be taking over First Republic, though, the stock's 75% tumble isn't a potential opportunity for investors.

  • Zacks

    Catalent (CTLT) Stock Jumps 6.8%: Will It Continue to Soar?

    Catalent (CTLT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • Zacks

    Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

    BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Motley Fool

    Why Catalent Stock Tumbled by Nearly 6% on Tuesday

    A warning about revenue and the abandonment of a potential suitor are recent developments that continue to hammer sentiment on the company.

  • Zacks

    Earnings Preview: Catalent (CTLT) Q3 Earnings Expected to Decline

    Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Motley Fool

    Why Catalent Stock Dove More Than 7% Today

    Extending its streak of declines, Catalent (NYSE: CTLT) stock fell again on Tuesday. A pair of analysts' price target cuts were the apparent catalysts for this latest slide. On Tuesday morning, prognosticators from Barclays (NYSE: BCS) and Deutsche Bank (NYSE: DB) made downward adjustments to their Catalent targets.

  • Zacks

    Catalent (CTLT) Declines on Profit Warnings and CFO Exit

    Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

  • Motley Fool

    Why Catalent Stock Slumped on Monday

    Contract drug manufacturer Catalent (NYSE: CTLT) was surely tempted to reach for the aspirin bottle on Monday. Bloomberg reported that morning that the conglomerate Danaher (NYSE: DHR) has dropped its pursuit of Catalent. Citing "people familiar with the matter," the Bloomberg report said Danaher is no longer considering making a buyout offer despite its earlier expression of interest.

  • Business Wire

    Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer

    SOMERSET, N.J., April 14, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced a business update. While complete financial information and operating data for the Company’s third fiscal quarter ended March 31, 2023 are not yet finalized, the Company expects that productivity issues and higher-than-expected costs experienced at three of its facilities, including two of its lar

  • Zacks

    Here's Why You Should Retain Catalent (CTLT) Stock for Now

    Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.